GT199800200AA - Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200). - Google Patents

Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200).

Info

Publication number
GT199800200AA
GT199800200AA GT199800200AK GT199800200K GT199800200AA GT 199800200A A GT199800200A A GT 199800200AA GT 199800200A K GT199800200A K GT 199800200AK GT 199800200 K GT199800200 K GT 199800200K GT 199800200A A GT199800200A A GT 199800200AA
Authority
GT
Guatemala
Prior art keywords
azapolyclic
aryl
compounds
derived
compounds condensed
Prior art date
Application number
GT199800200AK
Other languages
English (en)
Spanish (es)
Inventor
Jothan Wadsworth Coe
Paige Roanne Palmer Brooks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT199800200A(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT199800200AA publication Critical patent/GT199800200AA/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
GT199800200AK 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200). GT199800200AA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31

Publications (1)

Publication Number Publication Date
GT199800200AA true GT199800200AA (es) 2000-06-07

Family

ID=22094096

Family Applications (2)

Application Number Title Priority Date Filing Date
GT199800200A GT199800200A (es) 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo.
GT199800200AK GT199800200AA (es) 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GT199800200A GT199800200A (es) 1997-12-31 1998-12-15 Compuestos azapoliciclicos condensados con arilo.

Country Status (52)

Country Link
US (6) US6410550B1 (sk)
EP (2) EP1659114A3 (sk)
JP (1) JP3550359B2 (sk)
KR (1) KR100408138B1 (sk)
CN (2) CN1715280A (sk)
AP (1) AP1170A (sk)
AR (1) AR017967A1 (sk)
AT (1) ATE386024T1 (sk)
AU (1) AU753389C (sk)
BG (1) BG65058B1 (sk)
BR (2) BR9816186B1 (sk)
CA (1) CA2316921C (sk)
CO (1) CO4810373A1 (sk)
CY (2) CY1107391T1 (sk)
CZ (1) CZ301925B6 (sk)
DE (2) DE69839131T3 (sk)
DK (1) DK1044189T4 (sk)
DZ (1) DZ2697A1 (sk)
EA (1) EA003190B1 (sk)
EG (1) EG23816A (sk)
ES (1) ES2301210T5 (sk)
FR (1) FR08C0039I2 (sk)
GT (2) GT199800200A (sk)
HK (1) HK1031878A1 (sk)
HN (1) HN1998000177A (sk)
HR (2) HRP20000445B1 (sk)
HU (2) HU230297B1 (sk)
IL (2) IL136727A0 (sk)
IS (1) IS5514A (sk)
LU (1) LU91442I2 (sk)
MA (1) MA26589A1 (sk)
ME (1) ME00459B (sk)
MY (1) MY118163A (sk)
NL (1) NL300355I2 (sk)
NO (2) NO319115B1 (sk)
NZ (1) NZ504482A (sk)
OA (1) OA11428A (sk)
PA (1) PA8463901A1 (sk)
PE (1) PE20000053A1 (sk)
PL (1) PL209404B1 (sk)
PT (1) PT1044189E (sk)
RS (1) RS50069B (sk)
SA (1) SA99191123B1 (sk)
SG (1) SG102686A1 (sk)
SI (1) SI1044189T2 (sk)
SK (1) SK286886B6 (sk)
TN (1) TNSN98237A1 (sk)
TR (1) TR200001840T2 (sk)
TW (1) TW513412B (sk)
UA (1) UA66825C2 (sk)
WO (1) WO1999035131A1 (sk)
ZA (1) ZA9811911B (sk)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3550359B2 (ja) * 1997-12-31 2004-08-04 ファイザー・プロダクツ・インク アリール縮合アザ多環状化合物
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
MXPA03009527A (es) * 2001-04-20 2004-02-12 Pfizer Prod Inc PROCEDIMIENTO PARA LA PREPARACIoN DE INDENOS 1,3-SUSTITUIDOS Y COMPUESTOS AZAPOLICICLICOS CONDENSADOS CON ARILO.
CN100370987C (zh) * 2001-05-14 2008-02-27 辉瑞产品公司 5，8，14-三氮杂四环[10.3.1.02，11.04，9]-十六-2(11)，3，5，7，9-五烯的酒石酸盐
EP1390366B1 (en) * 2001-05-14 2005-08-31 Pfizer Products Inc. The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
RU2004116311A (ru) 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
EP1451202B1 (en) 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP1448235B1 (en) * 2001-11-30 2007-03-14 Pfizer Products Inc. Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
AU2003215272B2 (en) * 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
RS20050366A (en) * 2002-11-20 2007-12-31 Pfizer Products Inc., A method for preparing indan-1,3- dicarboxylic acid
AU2003294473A1 (en) * 2002-11-20 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
KR100655848B1 (ko) * 2002-11-25 2006-12-11 화이자 프로덕츠 인크. 1,3-치환된 인덴의 개선된 제조 방법
BRPI0406670A (pt) * 2003-01-15 2005-12-20 Pfizer Prod Inc Processo para a preparação de lactamas policìclicas fundidos com arila
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
MXPA05012507A (es) * 2003-05-20 2006-01-30 Pfizer Prod Inc Composiciones farmaceuticas de vareniclina.
PL378491A1 (pl) * 2003-06-04 2006-05-02 Pfizer Products Inc. Sposób wytwarzania podstawionych chinoksalin z dianiliny i z 2,3-dihydroksy-1,4-dioksanu
WO2005007630A2 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
BRPI0412712A (pt) * 2003-07-21 2006-09-26 Pfizer Prod Inc compostos azapolicìclicos fundidos com heteroarila
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
AU2006217616A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Preparation of high purity substituted quinoxaline
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
MX2008011549A (es) * 2006-03-27 2008-09-22 Pfizer Prod Inc Patrones de vareniclina y controles de impureza.
RU2403016C2 (ru) * 2006-04-24 2010-11-10 Пфайзер Продактс Инк. Асимметричные мембраны для устройств доставки лекарственного препарата
EP2083921A2 (en) 2006-09-04 2009-08-05 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
AU2007319951A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
WO2008115411A1 (en) * 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
EP2260037A2 (en) * 2008-02-15 2010-12-15 Medichem, S.A. A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2271344A4 (en) * 2008-03-31 2011-04-27 Univ South Florida METHODS OF TREATING DISEASE INDUCED ATAXIA AND NON-ATAXIC IMBALANCE
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010023561A1 (en) * 2008-09-01 2010-03-04 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
CN102388043A (zh) * 2009-02-11 2012-03-21 桑诺维恩药品公司 组胺h3反相激动剂和拮抗剂及其使用方法
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
MX2012002898A (es) * 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
AU2011225747A1 (en) 2010-03-09 2012-09-27 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
US20140128606A1 (en) 2011-06-30 2014-05-08 Toray Industries, Inc. Antipruritic agent
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
WO2018160043A1 (ko) 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
WO2023244584A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
JP3550359B2 (ja) * 1997-12-31 2004-08-04 ファイザー・プロダクツ・インク アリール縮合アザ多環状化合物
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
CA2330576A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Substituted benzazocines as nicotine-binding inhibitors
DE60006213T2 (de) * 1999-01-29 2004-07-29 Abbott Laboratories, Abbott Park Diazabicyloderivate als nikotin-acetylcholin-rezeptorliganden
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CN100370987C (zh) * 2001-05-14 2008-02-27 辉瑞产品公司 5，8，14-三氮杂四环[10.3.1.02，11.04，9]-十六-2(11)，3，5，7，9-五烯的酒石酸盐
EP1390366B1 (en) * 2001-05-14 2005-08-31 Pfizer Products Inc. The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
EP1451202B1 (en) * 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP1448235B1 (en) * 2001-11-30 2007-03-14 Pfizer Products Inc. Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2005007630A2 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds

Also Published As

Publication number Publication date
EP1044189B2 (en) 2015-02-25
YU40300A (sh) 2003-10-31
IS5514A (is) 2000-05-26
PT1044189E (pt) 2008-04-22
HRP20000445B1 (en) 2009-04-30
US20020111350A1 (en) 2002-08-15
ATE386024T1 (de) 2008-03-15
TNSN98237A1 (fr) 2005-03-15
US6887884B2 (en) 2005-05-03
SA99191123B1 (ar) 2006-10-02
NO2006016I2 (sk) 2008-10-20
US6410550B1 (en) 2002-06-25
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
US20020072525A1 (en) 2002-06-13
CA2316921A1 (en) 1999-07-15
CO4810373A1 (es) 1999-06-30
PA8463901A1 (es) 2000-09-29
BG104561A (en) 2001-01-31
JP3550359B2 (ja) 2004-08-04
CY2008013I1 (el) 2009-11-04
EA003190B1 (ru) 2003-02-27
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
DE122008000038I1 (de) 2008-11-13
CZ20002438A3 (cs) 2002-11-13
KR100408138B1 (ko) 2003-12-01
CA2316921C (en) 2004-12-07
BG65058B1 (bg) 2007-01-31
GT199800200A (es) 2000-06-07
NO319115B1 (no) 2005-06-20
DE69839131T2 (de) 2009-02-05
HUS1600018I1 (hu) 2018-05-02
LU91442I9 (sk) 2018-12-31
RS50069B (sr) 2009-01-22
UA66825C2 (uk) 2004-06-15
EG23816A (en) 2007-09-19
AP9801422A0 (en) 1998-12-31
US6951938B2 (en) 2005-10-04
NL300355I2 (nl) 2008-11-03
DE69839131D1 (de) 2008-03-27
CN1715280A (zh) 2006-01-04
BR9814592B1 (pt) 2010-06-01
CZ301925B6 (cs) 2010-08-04
MA26589A1 (fr) 2004-12-20
JP2002500218A (ja) 2002-01-08
IL136727A (en) 2006-06-11
DK1044189T3 (da) 2008-05-13
SI1044189T2 (sl) 2015-05-29
AU753389B2 (en) 2002-10-17
TW513412B (en) 2002-12-11
US6897310B2 (en) 2005-05-24
HRP20050506A2 (en) 2006-03-31
AU9641698A (en) 1999-07-26
EP1659114A2 (en) 2006-05-24
TR200001840T2 (tr) 2000-12-21
CN1285821A (zh) 2001-02-28
US20020072524A1 (en) 2002-06-13
ZA9811911B (en) 2000-06-29
SG102686A1 (en) 2004-03-26
PL209404B1 (pl) 2011-08-31
US20070275973A1 (en) 2007-11-29
AR017967A1 (es) 2001-10-24
HN1998000177A (es) 1999-02-09
KR20010033823A (ko) 2001-04-25
NL300355I1 (nl) 2008-08-01
AU753389C (en) 2007-08-09
SK9712000A3 (en) 2002-03-05
AP1170A (en) 2003-06-30
FR08C0039I2 (fr) 2009-12-18
HU230297B1 (hu) 2015-12-28
CY2008013I2 (el) 2009-11-04
SI1044189T1 (sl) 2008-06-30
NO20003422L (no) 2000-08-29
OA11428A (en) 2004-05-03
HK1031878A1 (en) 2001-06-29
BR9814592A (pt) 2000-10-17
PL341824A1 (en) 2001-05-07
CN1324013C (zh) 2007-07-04
ME00459B (me) 2011-10-10
CY1107391T1 (el) 2010-07-28
DZ2697A1 (fr) 2003-03-29
US20020132824A1 (en) 2002-09-19
NO2006016I1 (no) 2006-11-27
FR08C0039I1 (sk) 2008-11-14
SK286886B6 (sk) 2009-07-06
BR9816186B1 (pt) 2009-01-13
NO20003422D0 (no) 2000-06-30
EP1044189A1 (en) 2000-10-18
HUP0100949A3 (en) 2002-12-28
EP1659114A3 (en) 2007-01-17
DK1044189T4 (en) 2015-03-30
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
NZ504482A (en) 2003-01-31
DE69839131T3 (de) 2015-05-07
LU91442I2 (fr) 2008-07-21
MY118163A (en) 2004-09-30
IL136727A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
GT199800200AA (es) Compuestos azapoliciclicos condensados con arilo (solicitud fraccionaria no. 1, derivada de la patente pi-1998-0200).
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
GT199800058A (es) Derivados de nicotinamida.
ATE469132T1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
UY27258A1 (es) Derivados de dihidro-benzo b 1, 4 diazepin-2-ona como antagonistas ii mglur2
SE9502167D0 (sv) Insulinanalog-kompositioner
CR6620A (es) Amino acidos biciclicos como agentes farmaceuticos
ATE368458T1 (de) Chronische bolusgabe von d-threo methylphenidat
DE69802679D1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
BR9901279A (pt) Triciclicos substituìdos
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
GT199800032A (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas.
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
PT884316E (pt) Quinazolina-4-ona como antagonistas do mapa
GT199800205A (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos.
DE602004020042D1 (de) er SSRI zur Behandlung von Stimmungs- oder Angststörungen
AR010122A1 (es) Procedimiento de recuperacion de vwf altamente purificado o complejo de factor viii/vwf altamente purificado
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
ATE411283T1 (de) (20s)-1 alpha-hydroxy-2-methylen-19-nor- bishomopregnacalciferol und ihre verwendungen
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
BR0112131A (pt) Composições farmacêuticas e métodos para uso
PA8642901A1 (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i
DE69832302D1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
GT199800147A (es) Tetrahidronaftalenos substituidos y compuestos analogos.